OptiNose Inc (NASDAQ:OPTN) has been assigned a consensus broker rating score of 1.25 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company. OptiNose’s rating score has improved by 6% from three months ago as a result of various analysts’ ratings changes.
Analysts have set a 12-month consensus target price of $29.25 for the company and are predicting that the company will post ($0.46) earnings per share for the current quarter, according to Zacks. Zacks has also given OptiNose an industry rank of 187 out of 265 based on the ratings given to its competitors.
OPTN has been the topic of several research reports. Royal Bank of Canada initiated coverage on shares of OptiNose in a research report on Tuesday, November 7th. They set an “outperform” rating and a $33.00 price target on the stock. Piper Jaffray Companies set a $28.00 price target on shares of OptiNose and gave the stock a “buy” rating in a research report on Monday, January 15th. BMO Capital Markets initiated coverage on shares of OptiNose in a research report on Tuesday, November 7th. They set an “outperform” rating and a $29.00 price target on the stock. Finally, Jefferies Group initiated coverage on shares of OptiNose in a research report on Tuesday, November 7th. They set a “buy” rating and a $27.00 price target on the stock.
Shares of OptiNose (OPTN) opened at $18.44 on Tuesday. OptiNose has a 1 year low of $15.01 and a 1 year high of $21.50.
OptiNose (NASDAQ:OPTN) last issued its quarterly earnings results on Monday, November 27th. The company reported ($4.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($3.76). research analysts predict that OptiNose will post -1.33 earnings per share for the current year.
A number of large investors have recently modified their holdings of OPTN. Peregrine Capital Management LLC acquired a new stake in OptiNose in the fourth quarter valued at approximately $6,314,000. Kornitzer Capital Management Inc. KS acquired a new stake in OptiNose in the fourth quarter valued at approximately $6,040,000. Wells Fargo & Company MN acquired a new stake in OptiNose in the fourth quarter valued at approximately $5,392,000. American Century Companies Inc. acquired a new stake in OptiNose in the fourth quarter valued at approximately $1,745,000. Finally, Schwab Charles Investment Management Inc. acquired a new stake in OptiNose in the fourth quarter valued at approximately $432,000. 0.95% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/16/optinose-inc-optn-given-29-25-average-target-price-by-analysts.html.
OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.
Get a free copy of the Zacks research report on OptiNose (OPTN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.